OS

Lose the Nausea in Your Weight Loss Therapies

Your ability to succeed in launching a new drug for weight loss depends on how well you can mitigate the most noted side effect of current therapies: nausea.

Now with OBESITYsym™, you can predict and optimize your drug's efficacy for weight loss, range of weight loss, *and* decreased nausea side effects.

Why OBESITYsym?

OBESITYsym runs on the Thales QSP modeling platform, which allows you to generate validated, diverse simulation populations with a distribution of responses identical to clinical data—including temporal treatment and placebo responses. You can also feed in your existing clinical experience and data to optimize your predictions even further.

OBESITYsym can help you...

✅ Identify optimal dosing to maximize efficacy and minimize nausea

✅ Predict efficacy for obesity indication (such as weight loss over time and changes in body fat, lean body mass, and total body weight)

✅ Compare compounds in development against approved medications currently in use (such as semaglutide, liraglutide, and tirzepatide)

✅ Predict efficacy for treatment combinations

✅ Evaluate new mechanisms and targets (model can expand to include new targets and novel therapeutic approaches)